Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- DAC +25.9%, MTL +11.6%, JILL +10.9%, NX +4.9%, ADI +4%, DAKT +1.3%
M&A news:
- MNK +1.4% (Said to be mulling a possible sale of its generics unit)
Other news:
- XTNT +17.4% (OrbiMed Advisors affirms 9.99% stake, changes shareholding position to active from passive)
- ETRM +13% (announced that AMITA Health Adventist Medical Center successfully completed its first implant of the Company's vBloc Neurometabolic Therapy)
- EXAS +8.7% (Positive UNH coverage development)
- MBVX +5.7% (enters into a sponsored research agreement with Memorial Sloan Kettering Cancer Center for the development of novel CAR-T therapeutics)
- GLYC +4.3% (Continued strength; closes public offering of common stock)
- CLDT +4.2% (To join the S&P SmallCap 600)
- HTZ +3.4% (To offer $1 bln aggregate principal amount of senior second priority secured notes)
- ARRY +3.1% (Array Biopharma and Ono Pharma partner to develop and commercialization Binimetinib And Encorafenib)
- TNXP +1.9% (Highlights oral pipeline presentation)
- ERIC +1.5% (Cevian Capital discloses 5.57% active stake)
- ALNY +1.5% (receives Breakthrough Therapy designation from the FDA for givosiran)
- DBVT +1.2% (continued strength)
- AUPH +1% (Selected to present late breaking oral presentations)
- NVS +1% (holds investor event; expects the next growth phase to begin in 2018)
Analyst comments:
- FRO +5.7% (upgraded to Buy from Neutral at Seaport Global Securities
- GOGO +1.2% (initiated after the close last night with a Outperform at Raymond James)
- ECA +0.8% (initiated with a Outperform at Raymond James)